Cargando…

Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors

BACKGROUND: Radioembolization is one therapeutic option for the treatment of locally early-stage hepatocellular carcinoma. The aim of this study was to evaluate the distribution of Lipiodol® ultra-fluid and microspheres and to simulate their effectiveness with different beta emitters ((90)Y, (188)Re...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieudonné, Arnaud, Becker, Stéphanie, Soares, Miguel, Hollenbeck, Claire, De Goltstein, Marie-Christine, Vera, Pierre, Santus, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667182/
https://www.ncbi.nlm.nih.gov/pubmed/37995042
http://dx.doi.org/10.1186/s13550-023-01051-9
_version_ 1785149015732518912
author Dieudonné, Arnaud
Becker, Stéphanie
Soares, Miguel
Hollenbeck, Claire
De Goltstein, Marie-Christine
Vera, Pierre
Santus, Robin
author_facet Dieudonné, Arnaud
Becker, Stéphanie
Soares, Miguel
Hollenbeck, Claire
De Goltstein, Marie-Christine
Vera, Pierre
Santus, Robin
author_sort Dieudonné, Arnaud
collection PubMed
description BACKGROUND: Radioembolization is one therapeutic option for the treatment of locally early-stage hepatocellular carcinoma. The aim of this study was to evaluate the distribution of Lipiodol® ultra-fluid and microspheres and to simulate their effectiveness with different beta emitters ((90)Y, (188)Re, (32)P, (166)Ho, (131)I, and (177)Lu) on VX2 tumors implanted in the liver of 30 New Zealand rabbits. RESULTS: Twenty-three out of 30 rabbits had exploitable data: 14 in the group that received Lipiodol® ultra-fluid (group L), 6 in the group that received microspheres (group M), and 3 in the control group (group C). The histologic analysis showed that the Lipiodol® ultra-fluid distributes homogeneously in the tumor up to 12 days after injection. The X-ray μCT images showed that Lipiodol® ultra-fluid has a more distal penetration in the tumor than microspheres. The entropy (disorder of the system) in the L group was significantly higher than in the M group (4.06 vs 2.67, p = 0.01). Equivalent uniform biological effective doses (EUBED) for a tumor-absorbed dose of 100 Gy were greater in the L group but without statistical significance except for (177)Lu (p = 0.03). The radionuclides ranking by EUBED (from high to low) was (90)Y, (188)Re, (32)P, (166)Ho, (131)I, and (177)Lu. CONCLUSIONS: This study showed a higher ability of Lipiodol® ultra-fluid to penetrate the tumor that translated into a higher EUBED. This study confirms (90)Y as a good candidate for radioembolization, although (32)P, (166)Ho, and (188)Re can achieve similar results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-023-01051-9.
format Online
Article
Text
id pubmed-10667182
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106671822023-11-23 Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors Dieudonné, Arnaud Becker, Stéphanie Soares, Miguel Hollenbeck, Claire De Goltstein, Marie-Christine Vera, Pierre Santus, Robin EJNMMI Res Original Research BACKGROUND: Radioembolization is one therapeutic option for the treatment of locally early-stage hepatocellular carcinoma. The aim of this study was to evaluate the distribution of Lipiodol® ultra-fluid and microspheres and to simulate their effectiveness with different beta emitters ((90)Y, (188)Re, (32)P, (166)Ho, (131)I, and (177)Lu) on VX2 tumors implanted in the liver of 30 New Zealand rabbits. RESULTS: Twenty-three out of 30 rabbits had exploitable data: 14 in the group that received Lipiodol® ultra-fluid (group L), 6 in the group that received microspheres (group M), and 3 in the control group (group C). The histologic analysis showed that the Lipiodol® ultra-fluid distributes homogeneously in the tumor up to 12 days after injection. The X-ray μCT images showed that Lipiodol® ultra-fluid has a more distal penetration in the tumor than microspheres. The entropy (disorder of the system) in the L group was significantly higher than in the M group (4.06 vs 2.67, p = 0.01). Equivalent uniform biological effective doses (EUBED) for a tumor-absorbed dose of 100 Gy were greater in the L group but without statistical significance except for (177)Lu (p = 0.03). The radionuclides ranking by EUBED (from high to low) was (90)Y, (188)Re, (32)P, (166)Ho, (131)I, and (177)Lu. CONCLUSIONS: This study showed a higher ability of Lipiodol® ultra-fluid to penetrate the tumor that translated into a higher EUBED. This study confirms (90)Y as a good candidate for radioembolization, although (32)P, (166)Ho, and (188)Re can achieve similar results. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-023-01051-9. Springer Berlin Heidelberg 2023-11-23 /pmc/articles/PMC10667182/ /pubmed/37995042 http://dx.doi.org/10.1186/s13550-023-01051-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Dieudonné, Arnaud
Becker, Stéphanie
Soares, Miguel
Hollenbeck, Claire
De Goltstein, Marie-Christine
Vera, Pierre
Santus, Robin
Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors
title Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors
title_full Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors
title_fullStr Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors
title_full_unstemmed Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors
title_short Biological efficacy of simulated radiolabeled Lipiodol® ultra-fluid and microspheres for various beta emitters: study based on VX2 tumors
title_sort biological efficacy of simulated radiolabeled lipiodol® ultra-fluid and microspheres for various beta emitters: study based on vx2 tumors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667182/
https://www.ncbi.nlm.nih.gov/pubmed/37995042
http://dx.doi.org/10.1186/s13550-023-01051-9
work_keys_str_mv AT dieudonnearnaud biologicalefficacyofsimulatedradiolabeledlipiodolultrafluidandmicrospheresforvariousbetaemittersstudybasedonvx2tumors
AT beckerstephanie biologicalefficacyofsimulatedradiolabeledlipiodolultrafluidandmicrospheresforvariousbetaemittersstudybasedonvx2tumors
AT soaresmiguel biologicalefficacyofsimulatedradiolabeledlipiodolultrafluidandmicrospheresforvariousbetaemittersstudybasedonvx2tumors
AT hollenbeckclaire biologicalefficacyofsimulatedradiolabeledlipiodolultrafluidandmicrospheresforvariousbetaemittersstudybasedonvx2tumors
AT degoltsteinmariechristine biologicalefficacyofsimulatedradiolabeledlipiodolultrafluidandmicrospheresforvariousbetaemittersstudybasedonvx2tumors
AT verapierre biologicalefficacyofsimulatedradiolabeledlipiodolultrafluidandmicrospheresforvariousbetaemittersstudybasedonvx2tumors
AT santusrobin biologicalefficacyofsimulatedradiolabeledlipiodolultrafluidandmicrospheresforvariousbetaemittersstudybasedonvx2tumors